Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)
Clinical trial NCT02592798 · COMPLETED
Trial details
- NCT number
- NCT02592798
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-03-09
- Primary completion
- 2020-01-28
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.